Skip to content

US · AGIO · BIOTECHNOLOGY

Agios Pharmaceuticals, Inc. (AGIO) intrinsic value and stock valuation

$27.60as of 2026-11-21 · Mkt cap 1.93B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Agios Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values AGIO with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from AGIO’s statements →

Agios Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02139 agios.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$54M
20112025
Net income
-$-412.78M
20112025
Free cash flow
-$-377.29M
20112025
Total equity
$1.19B+24.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$54M$36.5M$26.8M$14.2M$0.00
Operating income-$-472.13M-$-425.74M-$-391.49M-$-389.05M-$-378.42M
Net income-$-412.78M$673.7M-$-352.09M-$-231.8M$1.6B
EPSd-$-7.12M$11.6M-$-6.33M-$-4.23M$26.5M
Operating cash flow-$-372.98M-$-389.84M-$-296.06M-$-309.48M-$-407.32M
Capital expenditure-$-4.32M-$-1.69M-$-1M-$-4.88M-$-5.74M
Free cash flow-$-377.29M-$-391.53M-$-297.06M-$-314.36M-$-413.06M
Total assets$1.3B$1.66B$937.1M$1.24B$1.44B
Total debt$40.2M$57M$72M$85.7M$97.1M
Net debt-$-48.92M-$-19.26M-$-16.21M-$-53.6M-$-106.03M
Total equity$1.19B$1.54B$811M$1.1B$1.29B
Cash and short-term investments$854.4M$893.7M$776.9M$783.1M$1.02B
Income statement
20252024202320222021
Revenue$54M$36.5M$26.8M$14.2M$0.00
Cost of revenue$11.5M$4.17M$9.5M$1.7M$18.8M
Gross profit$42.5M$32.3M$17.3M$12.5M-$-18.78M
Research and development expenses$334.4M$301.3M$288.9M$279.9M$257M
Selling, general and administrative expenses$180.3M$156.8M$119.9M$121.7M$121.4M
Other expenses$0.00$0.00$0.00$0.00-$-18.78M
Operating expenses$514.6M$458.1M$408.8M$401.6M$359.6M
Cost and expenses$526.2M$462.2M$418.3M$403.3M$378.4M
Interest income$56.4M$48.1M$33.3M$12.8M$840K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$5.18M$5.65M$6.62M$8.56M$18.8M
Ebitda-$-408.62M$723.6M-$-345.46M-$-223.24M-$-337.73M
Operating income-$-472.13M-$-425.74M-$-391.49M-$-389.05M-$-378.42M
Total other income/expenses, net$58.3M$1.14B$39.4M$157.3M$21.9M
Income before tax-$-413.8M$718M-$-352.09M-$-231.8M-$-356.51M
Income tax expense-$-1.02M$44.2M$0.00$0.00$0.00
Net income-$-412.78M$673.7M-$-352.09M-$-231.8M$1.6B
Weighted average shares outstanding$58M$56.8M$55.7M$54.8M$60.5M
Weighted average diluted shares outstanding$58M$57.9M$55.7M$54.8M$60.5M
Balance sheet
20252024202320222021
Cash and short-term investments$854.4M$893.7M$776.9M$783.1M$1.02B
Net receivables$10.6M$4.11M$2.81M$2.21M$4.38M
Inventory$32.9M$27.6M$19.1M$8.49M$0.00
Total current assets$942.1M$965.6M$833.8M$832.8M$1.06B
Property, plant and equipment, net$41.2M$54.6M$69.8M$88.1M$104.2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$310M$638.3M$29.4M$313.9M$266.4M
Total non-current assets$355.2M$697.6M$103.3M$406M$373.5M
Total assets$1.3B$1.66B$937.1M$1.24B$1.44B
Accounts payable$18.4M$16.6M$9.78M$18.6M$16.7M
Short-term debt$18.4M$16.8M$15M$13.7M$11.2M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$82.2M$81.2M$68M$62.6M$59.8M
Long-term debt$21.8M$40.2M$57M$72M$85.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$21.9M$41.1M$58.1M$75.3M$85.9M
Capital lease obligations$40.2M$57M$72M$85.7M$97.1M
Total liabilities$104.1M$122.2M$126.1M$137.9M$145.8M
Common stock$70K$70K$70K$70K$70K
Retained earnings-$-561.71M-$-148.92M-$-822.65M-$-470.56M-$-238.76M
Accumulated other comprehensive income (loss)$2.19M-$-1.52M-$-440K-$-12.54M-$-1.2M
Total equity$1.19B$1.54B$811M$1.1B$1.29B
Total investments$1.08B$1.46B$718.2M$957.7M$1.08B
Total debt$40.2M$57M$72M$85.7M$97.1M
Net debt-$-48.92M-$-19.26M-$-16.21M-$-53.6M-$-106.03M
Cash flow statement
20252024202320222021
Net income-$-412.78M$673.7M-$-352.09M-$-231.8M-$-356.51M
Depreciation and amortization$5.18M$5.65M$6.62M$8.56M$9.24M
Stock-based compensation$52.6M$42.9M$44.8M$49.3M$53.5M
Change in working capital-$-33.04M-$-19.77M-$-19.06M-$-16.43M-$-36.82M
Accounts receivable-$-6.47M-$-1.3M-$-600K-$-2.21M-$-4.38M
Inventory-$-5.3M-$-8.54M-$-10.58M-$-8.49M$0.00
Accounts payable$1.75M$6.6M-$-8.73M$3.44M$1.86M
Net cash provided by operating activities-$-372.98M-$-389.84M-$-296.06M-$-309.48M-$-407.32M
Investments in property, plant and equipment-$-4.32M-$-1.69M-$-1M-$-4.88M-$-5.74M
Acquisitions, net$0.00$40K$0.00$132.8M$0.00
Net cash used for investing activities$377.2M$363.4M$239.6M$243.3M$1.25B
Common stock issued$8.68M$14.4M$5.43M$2.68M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00-$-802.49M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.68M$14.4M$5.43M$2.35M-$-765.77M
Net change in cash$12.9M-$-11.96M-$-51.05M-$-63.87M$75.7M
Cash at end of period$89.1M$76.3M$88.2M$139.3M$203.1M
Operating cash flow-$-372.98M-$-389.84M-$-296.06M-$-309.48M-$-407.32M
Capital expenditure-$-4.32M-$-1.69M-$-1M-$-4.88M-$-5.74M
Free cash flow-$-377.29M-$-391.53M-$-297.06M-$-314.36M-$-413.06M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Agios Pharmaceuticals, Inc.

        Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.

        CEO
        Brian Goff
        Employees
        540
        Beta
        0.54

        Explore

        Frequently asked questions

        What is the intrinsic value of Agios Pharmaceuticals, Inc. (AGIO)?

        Agios Pharmaceuticals, Inc. (AGIO) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AGIO undervalued?

        AGIO trades at a price of $27.60 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.